Found 141 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands)
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives)
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
The purpose of this study is to compare the usual approach (observation) to using capecitabine and temozolomide. We will enroll patients with High-Risk Pancreatic Neuroendocrine Tumors. We will utilize CIRB as the IRB of Record.
The purpose of this study is to continue to collect long term information on the safety of pembrolizumab or pembrolizumab-based combinations that you received or are receiving as part of the protocol you are currently enrolled in, to see how well the drug/s work and how your body reacts to …
Primary Objective: a) To measure the proportion of breast cancer patients where Cerianna positron emission tomography (PET)/computed tomography (CT) detection of estrogen receptor (ER) status alters the preexamination intended therapeutic management Secondary Objectives: a) Per subject, to qualitatively assess heterogeneity in tumor Cerianna uptake relative to standard-of-care imaging b) Per …
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
Please refer to Protocol Section 3. (OBJECTIVES AND ENDPOINTS). Please refer to Protocol Section 3. (OBJECTIVES AND ENDPOINTS). Please refer to Protocol Section 3. (OBJECTIVES AND ENDPOINTS).
